

Special Issue

HIV Neurological Disorders: 2nd Edition

Message from the Guest Editor

It became apparent from the Special Issue on [HIV neurological disorders](#) that there are many unresolved challenges. These challenges include, but are not limited to, clinical manifestations, quantitative diagnosis measures, pathological mechanisms and treatment developments. This second Special Issue on HIV neurological disorders can address the different challenges clinicians and researchers are now facing. The mechanism(s) for the production of HIV neurologic disorders remains elusive and complex. In many parts of the world, opportunistic infections still present a continued challenge. Where treatment is available, patients may eventually present with HIV noninfectious comorbidities. Both these situations need to be addressed, but an underlying point in both is the presence of HIV-associated inflammation. The chronic inflammation associated with HIV infection is the main candidate for the production of HIV neurological comorbidity. There is a need for both clinical and basic science research addressing HIV neurologic comorbidity.

Guest Editor

Dr. Frank Denaro

Department of Biology, Morgan State University, Baltimore, MD 21251, USA

Deadline for manuscript submissions

30 November 2024



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/202212

Viruses
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).